Horizons in therapy for corneal angiogenesis

Area of Science:

• Ophthalmology
• Vascular Biology
• Regenerative Medicine

Background:

• Corneal neovascularization (CNV) involves limbal barrier breakdown and blood vessel formation in the cornea.
• CNV leads to severe visual impairment and is a significant clinical challenge.
• The cornea normally possesses an antiangiogenic privilege, resisting blood vessel growth.

Purpose of the Study:

• To review the angiogenic and antiangiogenic factors regulating corneal avascularity.
• To discuss current and emerging treatments for CNV.
• To explore future directions in managing corneal neovascularization.

Main Methods:

• Literature review of peer-reviewed articles and clinical trial data.
• Analysis of the molecular mechanisms underlying corneal angiogenesis.
• Synthesis of information on therapeutic interventions and their efficacy.

Main Results:

• CNV results from an imbalance favoring angiogenic factors over antiangiogenic factors.
• Current treatments include anti-VEGF therapies, corticosteroids, and surgical interventions.
• Numerous clinical trials are investigating novel therapeutic approaches.

Conclusions:

• Maintaining the cornea's antiangiogenic state is crucial for preventing CNV.
• Targeting angiogenic pathways offers promising therapeutic strategies.
• Further research is needed to optimize treatments and improve visual outcomes for CNV patients.